{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:06:47Z","timestamp":1768208807655,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.7759\/cureus.93543","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:50:41Z","timestamp":1759229441000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Atezolizumab-Induced Very Severe Aplastic Anemia"],"prefix":"10.7759","author":[{"given":"Vamshi","family":"Vadlapatla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel D","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2021.12.002","article-title":"Aplastic anemia: pathophysiology","volume":"59","author":"Giudice V","year":"2022","unstructured":"Giudice V, Selleri C. Aplastic anemia: pathophysiology. Semin Hematol. 2022, 59:13-20. 10.1053\/j.seminhematol.2021.12.002","journal-title":"Semin Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.11","article-title":"Clinical management of aplastic anemia","volume":"4","author":"Dezern AE","year":"2011","unstructured":"Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011, 4:221-30. 10.1586\/ehm.11.11","journal-title":"Expert Rev Hematol"},{"key":"ref3","unstructured":"FDA Adverse Events Reporting System (FAERS) Public Dashboard. (2023). Accessed. October 4, 2023: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/a...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5455\/IJMRCR.atezolizumab-non-small-cell-lung-cancer","article-title":"Immune suppression therapy in aplastic anemia secondary to atezolizumab in a patient with stage IV non-small cell lung cancer","volume":"4","author":"Cheng W","year":"2020","unstructured":"Cheng W, Brown E, Gorman M, et al.. Immune suppression therapy in aplastic anemia secondary to atezolizumab in a patient with stage IV non-small cell lung cancer. Int J Med Rev Case Rep. 2020, 4:1. 10.5455\/IJMRCR.atezolizumab-non-small-cell-lung-cancer","journal-title":"Int J Med Rev Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1057134","article-title":"Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis","volume":"14","author":"Guo Q","year":"2023","unstructured":"Guo Q, Zhao JN, Liu T, Gao J, Guo H, Cheng JM. Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis. Front Pharmacol. 2023, 14:1057134. 10.3389\/fphar.2023.1057134","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref7","unstructured":"Cancer immunotherapy treatment for NSCLC, ES-SCLC, HCC, & advanced melanoma. (2023). Accessed. October 12, 2023: https:\/\/www.tecentriq.com\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-745","article-title":"Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report","volume":"11","author":"Qiu G","year":"2022","unstructured":"Qiu G, Li S, Li B, et al.. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. Transl Lung Cancer Res. 2022, 11:2346-55. 10.21037\/tlcr-22-745","journal-title":"Transl Lung Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101439","article-title":"Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report","volume":"33","author":"Seguchi K","year":"2021","unstructured":"Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report. Respir Med Case Rep. 2021, 33:101439. 10.1016\/j.rmcr.2021.101439","journal-title":"Respir Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01767-0","article-title":"Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma","volume":"16","author":"Fukushima M","year":"2023","unstructured":"Fukushima M, Tajima K, Sasaki R, et al.. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma. Clin J Gastroenterol. 2023, 16:402-6. 10.1007\/s12328-023-01767-0","journal-title":"Clin J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220913081","article-title":"Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia","volume":"26","author":"Y\u0131lmaz A","year":"2020","unstructured":"Y\u0131lmaz A, Mirili C, Bilici M, Tekin SB. Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. J Oncol Pharm Pract. 2020, 26:1791-4. 10.1177\/1078155220913081","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13315","article-title":"Management of immune checkpoint inhibitor-related adverse events: a review of case reports","volume":"11","author":"Si X","year":"2020","unstructured":"Si X, Song P, Ni J, et al.. Management of immune checkpoint inhibitor-related adverse events: a review of case reports. Thorac Cancer. 2020, 11:498-504. 10.1111\/1759-7714.13315","journal-title":"Thorac Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211033009","article-title":"Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: cold agglutinin disease","volume":"27","author":"Acikgoz O","year":"2021","unstructured":"Acikgoz O, Bayramgil A, Cavusoglu G, Sadri S. Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: cold agglutinin disease. J Oncol Pharm Pract. 2021, 27:2066-8. 10.1177\/10781552211033009","journal-title":"J Oncol Pharm Pract"},{"key":"ref14","article-title":"Aplastic anemia","author":"Moore CA","year":"2025","unstructured":"Moore CA, Krishnan K. Aplastic anemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354554-a-rare-case-of-atezolizumab-induced-very-severe-aplastic-anemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:50:45Z","timestamp":1759229445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354554-a-rare-case-of-atezolizumab-induced-very-severe-aplastic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.93543","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}